UPDATE 1-US FDA approves BeOne's drug for a type of blood cancer

Adds details throughout

May 13 (Reuters) - BeOne Medicines 688235.SS said on Wednesday that the U.S. Food and Drug Administration has approved its drug for a type of blood cancer.

U.S.-listed shares of the company were up more than 1% in afternoon trade.

The drug, branded as Beqalzi, was greenlit to treat relapsed or refractory mantle cell lymphoma, an aggressive cancer of the lymphatic system, which contains disease-fighting white blood cells, that relapses after initial treatment or fails to respond to it.

The regulator's accelerated approval was based on a early-to-mid stage study in which the drug showed a complete response, or disappearance of all detectable signs of cancer, in 16% of the patients on the drug.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.